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Abstract
Nanotechnology is the new industrial revolution of the 21st Century as the various processes lead
to radical improvements in medicine, manufacturing, energy production, land remediation,
information technology and many other everyday products and applications. With this revolution
however, there are undoubted concerns for health, safety and the environment which arise from
the unique nature of materials and processes at the nanometre scale.
The in vitro assays used in the screening strategy are all validated, internationally accepted
protocols and provide a useful indication of potential toxicity of a chemical as a result of effects on
various toxicological endpoints such as local site of contact (dermal) irritation, general cytotoxicity
and mutagenicity.
The initial in vitro screening strategy described in this paper to investigate the potential health
implications, if any, which may arise following exposure to one specific application of
nanoparticulate cerium oxide used as a diesel fuel borne catalyst, reflects a precautionary approach
and the results will inform judgement on how best to proceed to ensure safe use.
Background
Nanotechnology is the production and application of
structures, devices and systems by controlling shape and
size at the nanometre scale (1 nanometre = 1 × 10-6 mm).
The range of structures covered by the term nanotechnol-
ogy is also extensive and encompasses existing materials
with at least one dimension of < 100 nm and includes
nanoparticulates of various metals and their oxides, as
well as more diverse engineered nanomaterials such as
carbon nanotubes (CNT) and fullerenes.
The downstream applications of nanotechnology are
equally diverse, from electronics and engineering, medic-
inal/medical diagnostic devices, remediation of environ-
mental pollution, personal care products and also food/
beverages as well as information technology. The general
public is already exposed to a variety of consumer prod-
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ucts containing nanoparticulates e.g. titanium dioxide in
paints, and cosmetic products, e.g. sunscreens containing
zinc oxide and/or titanium dioxide.
Envirox™ is a cerium oxide based fuel borne catalyst and
supplied as a dispersion of 2% w/v cerium oxide in a
hydrocarbon carrier (which is wholly compatible with
diesel). This is diluted with diesel for delivery to the vehi-
cle at a ratio of 1:4000, yielding a final cerium oxide con-
centration in the vehicle diesel fuel of 5 ppm. The efficacy
of Envirox™ is primarily due to the vastly increased surface
area of the nanoparticulate cerium oxide. Once in the
combustion chamber nanoparticulate cerium oxide works
to modify the combustion of diesel fuel while extending
and improving fuel burn. In addition the inclusion of
nanoparticulate cerium oxide reduces the temperature at
which carbon combusts. This feature provides a secondary
benefit to the performance of a diesel fuel engine, as it
facilitates the removal of hard carbon deposits and soot,
which further increases fuel efficiency and potentially
reduces wear in the engine and, most importantly, results
in reduced particulate emissions from the exhaust.
Despite the fact that humans have been exposed to nano-
sized particles throughout their evolution from natural/
anthropogenic sources, it is the proliferation of the new
(nano)materials which has prompted concerns to be
raised [1] over human health and environmental safety
following their suspected inevitable release into the envi-
ronment at some stage of the 'product application' lifecy-
cle. These concerns are intrinsically inter-linked with the
extremely small size of these particles. There is an inverse
relationship between particle size and surface area, i.e. the
smaller the particle the larger the surface area and the
greater the proportion of atoms or molecules which are
distributed on the surface rather than the interior of the
material. These surface changes may lead to an increase in
the number of 'reactive sites' on the particle which in turn
may lead to an increase in (eco)-toxicological effects [2,3].
In 2003 the UK Government commissioned a review, con-
ducted by the Royal Society and the Royal Academy of
Engineering [4], into the likely developments in nanote-
chnology and an examination of whether this would raise
new health and safety, environmental, social or ethical
issues which might lead to a requirement for new control-
ling legislation. This report, together with others [5,6],
identified a dearth of eco/toxicological hazard informa-
tion on nanomaterials that needed to be supplemented
prior to better understanding the potential risks, if any,
posed by manufactured nanoparticulates.
Recent publications [7-9] have begun the process required
to address the development of sound scientific strategies
for the safety evaluation, or hazard identification and
thence risk assessment of nanomaterials. The above pub-
lications agree that any robust approach to hazard identi-
fication for nanomaterials may be predicated upon the
following three elements:
- physical-chemical characterisation
- in vitro assays, and
- in vivo studies.
Robust characterisation of each test material is an essen-
tial prerequisite of any investigation to ensure that com-
parison of results between laboratories is based on sound
science. This characterisation may include measurement
of some, or all, of the following where appropriate: parti-
cle size and distribution, shape, agglomeration state, crys-
tal structure, chemical composition, porosity, surface
area, surface charge and surface chemistry.
In vitro assays of the test material in any given matrix allow
the examination of specific biological response(s) and/or
mechanism of action under controlled conditions which
are not easily studied in complex in vivo situations. The in
vitro assays used in the current preliminary human safety
assessment were employed to investigate local toxicologi-
cal effects (skin irritation), any immediate effects on the
structure, function or pathology of cells (cytotoxicological
effects) and whether there was any initial adverse effect on
the cell's genetic material (Ames test) using a variety of
readily available and well-characterised cells in culture.
Additional tests were conducted to address the potential
for adverse ecotoxicological and environmental fate
effects. The results of all these initial tests will be used to
inform the stepwise development of a comprehensive
testing and safety assessment strategy for nanoparticulate
cerium oxide.
The approach outlined in this paper describes an initial in
vitro preliminary screening strategy to examine the poten-
tial for human health hazards following exposure to nan-
oparticulate cerium oxide. All of the tests conducted have
included non-nanoparticulate cerium oxide as a reference
material for comparison with nano cerium oxide. The
work was carried out within the departments for Alterna-
tive Testing and Genetic Toxicology at SafePharm Labora-
tories Ltd (SPL), Derby UK and is part of a broader
investigation of potential health effects.
Results
Characterisation of test materials
Data generated from a series of tests to characterise the
two forms of cerium oxide used as test materials in the
subsequent assessments of toxicological potential are
shown in Table 1.Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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Transmission Electron Microscopy (TEM) photographs of
each of the nanoparticulate and non-nanoparticulate
cerium oxide samples are shown in Figures 1 and 2. There
are significant differences in particle size in the two test
material samples and this is clearly illustrated in the pho-
tographs.
Epiderm™ skin model
Table 2 illustrates the mean OD540 and mean viability for
tissues exposed to the test materials. The nano-cerium
oxide and the non-nano cerium oxide test materials did
not directly reduce MTT.
The ET50 values for the nano cerium oxide, 1% (w/v) Tri-
ton X-100 the positive control and 1% of 20% (w/v) SLS
a standard reference material were 1517.18, 260.10 and
20.68 minutes respectively. The non-nano cerium oxide
was assayed at a later time than the nano cerium oxide
material and the corresponding ET50 values for non-nano
cerium oxide, the positive control and the reference mate-
rial were > 1440, 410.60 and 46.22 minutes respectively.
Using the equation below the Mean Irritation Potential
(MIP) for both the nano- and non-nano cerium oxide test
materials was calculated and determined as 0.01 for nano
cerium oxide and 0.03 for non-nano cerium oxide.
Since both nano and non-nano cerium oxide test materi-
als had MIP values which were < 0.8 neither was consid-
ered to have the potential to be an in vivo skin irritant [10].
Based upon a recent statement from the European Centre
for the Validation of Alternative Methods (ECVAM) the
Epiderm model reliably identifies skin irritants [11] but
negative results may require further testing in line with
current guidance for this endpoint as described in the
OECD TG 404.
Cytotoxicity assay
The mean cytotoxicity/reactivity grades, related to the con-
centration and toxicity of soluble components diffusing
from the test sample, are illustrated in Table 3. The nega-
tive control (polypropylene pipette tips) had a cytotoxic-
ity grade of 0 and the positive control (tin-impregnated
PVC strips) showed evidence of a moderate cytotoxicity
MIP calculation equation MIP
ET  reference  material
ET
:
()
= 50
50   test  material ()
Non-nanoparticulate cerium oxide Figure 2
Non-nanoparticulate cerium oxide.
Table 1: Physico-chemical characteristics of the test materials
Test Property Nano Non-Nano
XRD Crystal Form Cerianite Cerianite
EDX Gross Elemental Analysis Ce, O Ce, O
BET Surface Area 94.7 m2/g 2.64 m2/g
Mean Particle Size 9 nm 320 nm
XPS Surface Chemistry Ce, O Ce, O
Nanoparticulate cerium oxide Figure 1
Nanoparticulate cerium oxide.Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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with a grade 3 score; thus indicating that the assay system
is reliable. Both non-nano particulate cerium oxide and
nanoparticulate cerium oxide showed no evidence of
cytotoxicity and each had a cytotoxicity grade of 0.
Ames test
Neither of the two cerium oxide particulate samples (non-
nano cerium oxide and nano-cerium oxide) were toxic to
Salmonella strain TA100 when tested in a preliminary tox-
icity assay and nor did either of the two test materials
cause any visible reduction in the growth of the bacterial
background lawn at any dose level. Therefore the two
cerium oxide particulate test materials were tested up to
the maximum recommended dose level of 5000 μg/plate.
Non-nano cerium oxide precipitation was not observed
on the plates at any of the doses tested in either the pres-
ence or absence of S9-mix. A cream-coloured film was
observed at 1500 μg/plate and above with an associated
precipitateat 5000 μg/plate in the case of the nanopartic-
ulate cerium oxide tested material (the observation of a
precipitate of a test sample is a routine means of ensuring
that the test has been performed adequately). These obser-
vations did not, however, prevent the scoring of revertant
colonies and confirmed that the samples were tested up to
a maximal dose level.
There were no significant increases in the frequency of
revertant colonies recorded for any of the strains of Salmo-
nella, at any dose level, either with or without metabolic
activation, for either the non-nano cerium oxide or nano-
particulate cerium oxide (Table 4, 5, 6, 7, 8, 9). All of the
positive control chemicals used in the study induced
marked increases in the frequency of revertant colonies
thus confirming the activity of the S9-mix and the sensi-
tivity of the bacterial strains.
Daphnia magna immobilisation study
There were no toxic effects observed i.e. no immobilisa-
tion occurred at any time period during this test.
The 48-hour EC50 for nano and non-nano cerium oxide to
Daphnia magna magna based on nominal test concentra-
tions was greater than 100% (v/v) saturated solution (see
Table 10) and correspondingly the No Observed Effect
Concentration (NOEC) was 100% (v/v) saturated solu-
tion.
Activated sludge respiration inhibition study
The 3-hour EC50 for inhibition of respiration of activated
sewage sludge bacteria for both nano cerium oxide and
non-nano cerium oxide test materials was greater than
1000 mg/l (see Table 11). There was no effect on the res-
piration of activated sewage sludge following a 3-hour
exposure to either of the test materials at 1000 mg/l i.e. No
Observed Effect Concentration (NOEC) = 1000 mg/l.
Discussion
Literature data on the potential adverse health effects of
particulate cerium oxide are not extensive [12] and an
assessment of existing data suggests that the inherent tox-
icity of cerium oxide is low. The authors are not aware of
any reviews of nanoparticulate cerium oxide toxicology
appearing in any of the more well-known journals where
Table 3: Results of the cytotoxicity testing
TEST MATERIAL MEAN CYTOTOXICITY/
REACTIVITY GRADE
Culture medium (Control) 0
Negative control 
(polypropylene pipette tips)
0
Positive control 
(tin-impregnated PVC strips)
3
'Non-nano' particulate CeO2 0
Nano-particulate CeO2 0
Table 2: Results of the Epiderm™ skin model study
Test Materials Exposure time (mins.) Mean OD540 % Viability ET50 mins. MIP
NEGATIVE CONTROL 960 1.685 100
1440
NANO-CeO2 960 2.010 119.29 1517.18 <0.01
1200 1.138 67.54
1440 1.089 64.63
NON-NANO CeO2 960 1.994 92.87 > 1440 0.03
1200 1.975 97.36
1440 1.729 85.23
POSITIVE CONTROL 1% TX100 240 1.035 61.42 260.10 <0.18
360 0.212 12.58
480 0.095 5.64
REFERENCE MATERIAL 20% SLS 15 0.983 58.34 20.68 1.00
30 0.710 42.14
60 0.273 16.20
120 0.100 5.93Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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English is the language of choice. However, it should be
remembered that a given mass of nanoparticles has a
much greater surface area than the same mass of fine, yet
respirable particles (see Table 12 from [13]) and thus is
potentially more reactive at the cellular level.
Based upon earlier inhalation studies with a variety of
nanoparticles of differing solubility [14] and surface reac-
tivity (but not cerium oxide), effects reported at the cellu-
lar level included those associated with the defensive
activities of lung macrophages engaged in the phagocyto-
sis of these nanoparticles, and, to the concurrent induc-
tion of oxidative stress coupled to (pro)-inflammatory
processes [15].
A pivotal feature of the preliminary safety studies reported
above was to mirror the approach already routinely
applied by industry and regulators when assessing health
and environmental hazards of chemicals within Europe.
Cerium oxide is an 'existing chemical' (listed on the Euro-
pean Inventory of Existing Commercial Chemical Sub-
stances: EINECS), only the form i.e. the size of the
chemical particles has been modified in the nano cerium
oxide test material. The objective of the preliminary
screening strategy was to compare the potential toxicity of
nano and non-nano forms of cerium oxide in a limited set
of in vitro assays. The results would then inform judge-
ment on the strategy to be adopted for a comprehensive
safety assessment should these data indicate that the nano
cerium oxide posed any additional health risks compared
to non-nano cerium oxide.
Results of the preliminary in vitro screening approach
reported here with a limited number of assays are clearly
negative. Based on the available hazard data these studies
do not raise any significant concerns for potential adverse
human health or environmental effects as a result of lim-
ited localised exposure of cells or aquatic organisms to
nano cerium oxide. Indeed the current information from
these preliminary studies does not indicate any difference
in cellular response following exposure to nanoparticu-
late cerium oxide when compared to that of non nano
cerium oxide.
The preliminary safety testing approach described in this
paper is consistent with the initial part of a screening test
Table 5: Results of bacterial gene point mutation assay. Cerium oxide – non-nanoparticulate. Summary of mean revertant colonies 
obtained
Experiment 2
Substance Dose Level (μg/plate) TA100 TA1535 TA102 TA98 TA1537
Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D.
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
DMSO 100 μl 93 ± 16 105 ± 13 27 ± 7 9 ± 1 345 ± 17 374 ± 13 20 ± 3 27 ± 7 8 ± 3 13 ± 4
Cerium Oxide Non-nano 50 87 ± 10 115 ± 10 32 ± 2 11 ± 7 349 ± 42 352 ± 31 16 ± 7 23 ± 2 15 ± 4 19 ± 4
150 95 ± 4 91 ± 8 28 ± 7 14 ± 2 343 ± 20 397 ± 21 20 ± 3 23 ± 2 8 ± 4 19 ± 5
500 94 ± 13 89 ± 4 37 ± 5 9 ± 1 349 ± 27 364 ± 23 18 ± 2 29 ± 3 9 ± 1 17 ± 3
1500 82 ± 2 99 ± 2 33 ± 12 9 ± 3 351 ± 22 380 ± 10 17 ± 2 28 ± 4 8 ± 4 21 ± 6
5000 107 ± 2 97 ± 13 26 ± 4 10 ± 2 350 ± 49 382 ± 21 18 ± 4 23 ± 6 15 ± 5 19 ± 3
S.D. Standard deviation
Table 4: Results of bacterial gene point mutation assay. Cerium oxide – non-nanoparticulate. Summary of mean revertant colonies 
obtained
Experiment 1
Substance Dose Level (μg/plate) TA100 TA1535 TA102 TA98 TA1537
Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D.
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
DMSO 100 μl 83 ± 7 64 ± 5 40 ± 2 12 ± 2 309 ± 24 333 ± 29 21 ± 5 26 ± 4 10 ± 2 17 ± 3
Cerium Oxide Non-nano 50 85 ± 12 73 ± 11 37 ± 5 13 ± 1 333 ± 28 361 ± 29 19 ± 4 29 ± 2 12 ± 2 19 ± 6
150 96 ± 7 70 ± 9 34 ± 3 11 ± 2 341 ± 21 359 ± 7 19 ± 3 29 ± 3 13 ± 3 18 ± 3
500 80 ± 12 76 ± 10 35 ± 7 11 ± 2 345 ± 9 367 ± 11 22 ± 7 29 ± 6 13 ± 3 20 ± 4
1500 69 ± 10 75 ± 11 34 ± 2 13 ± 6 338 ± 10 350 ± 26 16 ± 2 25 ± 3 12 ± 5 21 ± 5
5000 84 ± 7 73 ± 9 36 ± 3 10 ± 2 313 ± 21 354 ± 14 16 ± 4 31 ± 4 11 ± 1 22 ± 1Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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battery approach to identify whether or not the nanopar-
ticulate form of a substance is likely (or not) to cause sig-
nificant different adverse effects to those of the non-nano
substance which emerged from an opinion issued by the
EU Scientific Committee on Emerging and Newly Identi-
fied Health Risks (SCENIHR) on the appropriateness of
existing safety testing approaches for the assessment of
any potential risks associated with nanotechnologies [16].
The SCENIHR report states that where the nanoparticulate
has similar hazard properties to other physical forms of
the substance then existing studies (in vitro) combined
with information on the physicochemical characteristics
may lead to the overall conclusion that further work on
hazard assessment of the nanoparticulate form may not
be necessary. However, we recognise that the in vitro haz-
ard data currently reported is limited, it is simply Phase 1
of a comprehensive safety assessment work programme,
and that further work is needed before we can be satisfied
of the safety in use of nano cerium oxide in Envirox™ as a
diesel fuel additive.
Further support for the stepwise approach to safety assess-
ment of nano cerium oxide reported here is provided by
the UK Committees on Toxicity, Mutagenicity and Carci-
nogenicity of Chemicals in Food, Consumer Products and
the Environment (COT, COM, COC) [17]. These august
bodies were tasked to provide advice on the development
of nanotechnology to the UK Government and proposed
a systematic tiered approach for initial toxicological stud-
ies on novel nanomaterials based on in vitro screening of
selected materials to be supported by biodistribution
studies to aid in the identification of the cell types for
study, followed by appropriate in vivo testing to address
any endpoints of concern.
Conclusion
The preliminary screening studies reported in this paper
employed an in vitro approach to hazard identification of
nanoparticulate cerium oxide and benchmark any effects
by comparison with non-nano cerium oxide.
Table 7: Results of bacterial gene point mutation  assay. Cerium oxide - nanoparticulate. Summary of mean revertant  colonies 
obtained
Experiment 2
Substance Dose Level (μg/plate) TA100 TA1535 TA102 TA98 TA1537
Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D.
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
DMSO 100 μl 97 ± 14 132 ± 8 28 ± 6 30 ± 11 394 ± 9 380 ± 25 21 ± 5 38 ± 7 12 ± 10 15 ± 6
Cerium Oxide Nano 50 99 ± 19 123 ± 17 32 ± 2 29 ± 5 359 ± 28 397 ± 39 21 ± 4 33 ± 10 12 ± 1 13 ± 6
150 98 ± 20 127 ± 10 35 ± 6 40 ± 6 361 ± 32 391 ± 32 22 ± 4 32 ± 2 14 ± 7 12 ± 4
500 84 ± 6 126 ± 11 35 ± 11 32 ± 4 382 ± 29 350 ± 7 21 ± 4 32 ± 5 14 ± 4 16 ± 4
1500 (F) 92 ± 8 133 ± 7 36 ± 8 36 ± 7 361 ± 43 313 ± 29 19 ± 5 37 ± 4 9 ± 3 12 ± 3
5000 (F+P+M) 95 ± 3 121 ± 22 28 ± 5 29 ± 3 371 ± 24 353 ± 36 19 ± 3 26 ± 3 9 ± 1 17 ± 2
S.D. Standard deviation
F Film
P Precipitate
M Manual Count
Table 6: Results of bacterial gene point mutation  assay. Cerium oxide - nanoparticulate. Summary of mean revertant  colonies 
obtained
Experiment 1
TA100 TA1535 TA102 TA98 TA1537
Substance Dose Level (μg/plate) Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D.
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
DMSO 100 μl 118 ± 7 97 ± 13 39 ± 3 32 ± 6 347 ± 29 351 ± 4 28 ± 3 36 ± 7 13 ± 5 22 ± 2
Cerium Oxide Nano 50 100 ± 3 109 ± 17 37 ± 2 29 ± 13 356 ± 10 363 ± 25 23 ± 5 36 ± 2 11 ± 5 18 ± 4
150 88 ± 13 115 ± 9 40 ± 3 36 ± 1 360 ± 13 381 ± 20 25 ± 6 35 ± 6 12 ± 5 15 ± 5
500 84 ± 16 114 ± 20 33 ± 3 36 ± 3 377 ± 12 350 ± 17 26 ± 6 35 ± 7 14 ± 5 17 ± 4
1500 (F) 101 ± 13 115 ± 8 28 ± 4 32 ± 9 343 ± 38 330 ± 17 22 ± 3 35 ± 1 14 ± 4 24 ± 2
5000 (F+M+P) 101 ± 4 113 ± 7 39 ± 3 38 ± 2 343 ± 16 332 ± 14 23 ± 4 37 ± 4 12 ± 2 20 ± 5Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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The initial screening studies for human health which
included local site of contact (dermal) irritation, general
cytotoxicity and mutagenicity and environmental effects
(acute Daphnia magna toxicity and activated sludge respi-
ration inhibition) demonstrated no differences in biolog-
ical effects potential between nano and non-nano cerium
oxide.
These data support the conclusion of a lack of any addi-
tional (eco)-toxicological effects potential for nano-
cerium oxide when compared to that of non-nano cerium
oxide in a number of in vitro assays undertaken as a pre-
liminary toxicity screen.
Methods
Characterisation of the test materials used in subsequent 
in vitro assays
Cerium oxide samples used in these assays were character-
ised using a variety of analytical techniques including
XRD (X-ray diffraction), EDX (Energy Dispersive X-ray
analysis), BET (Brunauer Emmett Teller Surface Area), XPS
(X-ray Photoelectron Spectroscopy) and TEM (Transmis-
sion Electron Microscopy).
Sample (1) – Nanoparticulate cerium oxide was received
as an aqueous slurry at an approximate concentration of
8%w/w. Physico-chemical characterisation was con-
ducted on this form (as supplied) or after freeze drying.
Sample (2) – Non-nanoparticulate cerium oxide was
defined as "Cerium (IV) oxide, powder, <5 micron, 99.9%
pure, Aldrich catalogue number 211575".
In vitro assays
Three in vitro assay protocols were used in this screening
approach to investigate potential health hazards follow-
ing exposure to nanoparticulate and non-nanoparticulate
cerium oxide and comprised:
(a) EpiDerm™ Skin Irritation Test
(b) BS EN ISO 10993-5 Cytotoxicity assay
(c) 'Ames test' – OECD 471/EC B14 method
(a) The EpiDerm™ 'EPI-200' human epidermal model
The EpiDerm™ EPI-200 human epidermal model from
MatTek Corporation (Ashland, MA, USA) was utilised in
this preliminary screening approach for assessment of the
safety of Envirox™ since the skin is a potential route of
exposure during the formulation and use of the nano-
cerium oxide containing diesel fuel additive when acci-
dental skin contamination might reasonably be expected
to occur.
Table 9: Results of bacterial gene point mutation  assay. Positive control data.
Experiment 2
TA100 TA1535 TA102 TA98 TA1537
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
Compound ENNG 2AA ENNG 2AA MMC DAN 4NQO BP 9AA 2AA
Dose Level 3 μg1   μg5   μg2   μg0 . 5   μg1 0   μg0 . 2   μg5   μg8 0   μg2   μg
Mean ± S.D. 687 ± 88 1055 ± 181 706 ± 38 304 ± 49 1370 ± 86 832 ± 53 247 ± 8 353 ± 84 1909 ± 192 207 ± 44
S.D. Standard deviation
ENNG N-Ethyl-N'-nitro-N-nitrosoguanidine
MMC Mitomycin C
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
2AA 2-Aminoanthracene
DAN 1,8-dihydroxyanthraquinone
BP Benzo-a-Pyrene
Table 8: Results of bacterial gene point mutation  assay. Positive control data.
Experiment 1
TA100 TA1535 TA102 TA98 TA1537
(-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9) (-S9) (+S9)
Compound ENNG 2AA ENNG 2AA MMC DAN 4NQO BP 9AA 2AA
Dose Level 3 μg1   μg5   μg2   μg0 . 5   μg1 0   μg0 . 2   μg5   μg 80 μg2   μg
Mean ± S.D. 716 ± 35 669 ± 23 731 ± 71 212 ± 4 1338 ± 103 717 ± 38 238 ± 17 213 ± 8 789 ± 79 305 ± 7Particle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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Table 10: Cumulative immobilisation data in definitive Daphnia test
Nominal concentration (% v/v saturated solution) Cumulative immobilised Daphnia (initial population: 10 per replicate)
24-hour 48-hour
Number per replicate Total % Number per replicate Total %
Control:
R1 0 0
R2 0 0 0 0 0 0
R3 0 0
R4 0 0
100% Nano cerium oxide:
R1 0 0
R2 0 0 0 0 0 0
R3 0 0
R4 0 0
100% Non nano cerium oxide:
R1 0 0
R2 0 0 0 0 0 0
R3 0 0
R4 0 0
R1 R2 R1 R2
Positive control (mg/l) (potassium dichromate):
0.32 0 0 0 0 0 0 0 0
0.56 0 0 0 0 0 0 0 0
1.0 2 4 6 30 10 10 20 100
R1 – R4 = Replicates 1 to 4
Table 11: Oxygen consumption rates and percentage inhibition values in the definitive ASRIT test after 3-h contact time
Nominal concentration 
(mg/l)
Initial O2 reading 
(mg O2/l)
Measurement period 
(minutes)
Final O2 reading 
(mg O2/l)
O2 consumption rates 
(mg O2/l/min)
% inhibition
Control:
R1 6.9 10 2.9 0.40 -
R2 6.6 10 2.4 0.42 -
R3 6.9 10 2.8 0.41 -
R4 6.3 8 3.0 0.41 -
Nano cerium oxide:
1000 R1 6.7 10 2.5 0.42 [2]
1000 R2 6.8 10 2.8 0.40 2
1000 R3 6.5 9 2.9 0.40 2
Non-nano cerium oxide:
1000 R1 6.7 9 3.0 0.41 0
1000 R2 6.7 10 2.6 0.41 0
1000 R3 6.8 10 2.8 0.40 2
3,5-dichlorophenol (Reference material):
a) 3.2 7.3 10 4.4 0.29 29
b) 10 7.5 10 5.7 0.18 56
c) 32 8.2 10 7.4 0.08 80
d) 3.2 7.1 10 4.2 0.29 29
e) 10 7.7 10 6.0 0.17 59
f) 32 8.2 10 7.5 0.07 83
R1–R2 controls for nano cerium oxide test
R3–R4 controls for non-nano cerium oxide test
(a – c) reference samples for nano cerium oxide test
(d – f) reference samples for non nano cerium oxide testParticle and Fibre Toxicology 2007, 4:12 http://www.particleandfibretoxicology.com/content/4/1/12
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The EpiDerm™ study methodology used in this investiga-
tion was developed in-house at MatTek [18]. An exposure
time range-finding study was performed to establish the
appropriate range of exposure times to be used in the
main study.
(b) BS EN ISO 10993-5 Cytotoxicity Test
The BS EN ISO 10993-5 cytotoxicity test was selected as
the endpoint of the assay is a qualitative and semi-quanti-
tative estimate of toxicity that is non-specific in terms of
mechanism. Therefore, it is a robust procedure for the
detection of any potential for cell toxicity and may be con-
sidered to be a highly sensitive in vitro indicator test for the
prediction of in vivo toxicity.
The assay was used as described in the ISO methodology
[19] and a comparison made between the responses of
test materials and those of the positive control (tin-
impregnated plastic strip), the negative control (polypro-
pylene tip) and culture medium control to determine if
there were any differences in morphology or cell numbers.
This qualitative evaluation was translated into a semi-
quantitative score as 'cytotoxic response' rated on a scale
of 0 to 4, as shown in Table 13.
(c) Ames test
The OECD 471 Ames test was selected as the logical first
assay to determine the mutagenic potential of nano and
non-nano cerium oxide because it has both high sensitiv-
ity and specificity. The bacterial gene point mutation assay
is the primary in vitro screening method used in the eval-
uation of chemicals, pharmaceuticals, plant protection
products and other materials. It has been comprehen-
sively validated over the last 30 years and has been
applied in the testing of tens of thousands of products.
Salmonella typhimurium strains TA 98, 100, 102, 1535 &
1537 were used as recommended in the OECD 471 test
guideline methodology (see Table 14) for the general
screening of chemicals for mutagenicity [20] and results
confirmed by statistical methods [21].
A range of concentrations (50 – 5000 μg/plate in triplicate
based on a preliminary test) of both nano and non-nano
cerium oxide were prepared as suspensions in dimethyl
sulphoxide using a vortex mixer and sonication since they
were not soluble in water or common solvents. A solvent
control and a range of positive control test materials were
employed in the assay and included:-
(a) in the absence of metabolic activation (-S9): N-ethyl-
N'-nitro-N-nitrosoguanidine (ENNG) at 3 μg/plate for
TA100 and 5 μg/plate for TA1535, 9-Aminoacridine
(9AA) at 80 μg/plate for TA1537, Mitomycin C (MMC) at
0.5  μg/plate for TA102 and 4-Nitroquinoline-1-oxide
(4NQO) at 0.2 μg/plate for TA98, and (b) in the presence
of metabolic activation (+S9): 2-Aminoanthracene (2AA)
at 1 μg/plate for TA100, 2 μg/plate for TA1535 and
TA1537, Benzo(a)pyrene (BP) at 5 μg/plate for TA98 and
1,8-Dihydroxyanthraquinone (DAN) at 10 μg/plate for
TA102.
Ecotoxicity/environmental fate studies
Acute toxicity for Daphnia magna
The method was that updated by the OECD Expert Group
on Ecotoxicology in April 2004 [22]. As a consequence of
the poor water solubility of both nano and non-nano
cerium oxide a modification of the standard preparation
of aqueous media, as endorsed by ECETOC and OECD
[23,24] was employed. This adaptation allowed for the
exposure of Daphnia magna to a saturated solution of
Table 14: Chemical effects on various Salmonella typhimurium 
strains
TA100 sensitive to agents inducing base-pair substitution
TA1535 sensitive to agents inducing base-pair substitution
TA102 sensitive to agents inducing base-pair substitution
TA1537 sensitive to agents inducing frame-shift mutations
TA98 sensitive to agents inducing frame-shift mutations
Table 12: Correlation of particle diameter with surface area
Airborne mass concentration (μg/m3) Particle diameter (μm) Particles/ml of air Particle surface area (μ2/ml air) (μ2/ml air)
10 2 1.2 24
10 0.5 153 120
10 0.02 2400000 3016
Table 13: Semiquantitative score of cytotoxic response for BS 
EN ISO 10993-5 Cytotoxicity Test
Grade Cytotoxicity/
Reactivity
Description of Cytotoxicity/
Reactivity Zone
0 None No detectable zone around or under 
specimen
1 Slight Some malformed or degenerated cells
2 Mild Zone limited to area under specimen
3 Moderate Zone extends 0.5 to 1.0 cm beyond 
specimen
4 Severe Zone extends greater than 1.0 cm beyond 
specimen but does not involve entire dishPublish with BioMed Central    and   every 
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these high purity but poorly water soluble cerium oxide
test materials.
Activated sludge respiration inhibition test
The methodology is described in OECD test guideline 209
[16].
The test materials, both nano and non-nano cerium oxide
were dispersed directly in water. This approach allowed
for assessment of any effects of excess undissolved test
material on the activated sludge micro-organisms exoen-
zymes and also allowed for an evaluation of the uptake of
undissolved test material by processes such as phagocyto-
sis which may adversely affect activated sewage sludge.
Additionally this procedure allowed for an examination
of the entire waste water treatment facility with regards to
possible initial contact toxicity.
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